| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f46ad089e467ec263c09529771ace4c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00f26822cfc3af7bd1194f6e44f82033 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7064 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
2009-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f575449c6cdb27ce84409986d0e62be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_404771fe38ce0867376ea08aa0b19a4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae4108d4828814acb9247f02814fcc63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be116069f6a41536bb2adf05766feac6 |
| publicationDate |
2009-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009298786-A1 |
| titleOfInvention |
Methods of treating viral infections with anthracycline antibiotics |
| abstract |
A method of treating hepatitis C viral infection or viremia in a patient by administering to the patient an anti-hepatitis C virally effective amount of a compound of Formula 1 or Formula 2. A method for inhibiting the replication of hepatitis C virus by exposing the virus to a hepatitis C viral NS3 protease inhibiting amount of: a compound of Formula 1 or Formula 2. A pharmaceutical composition exhibiting an antihelicase activity containing at least a pharmaceutically-acceptable carrier, diluent or excipient, and a compound of Formula 1 or Formula 2. The pharmaceutical composition may additionally contain a second compound of Formula 1 or Formula 2; epidoxorubicin, doxorubicin, epidaunorubicin, or daunorubicin; and/or another antiviral agent. |
| priorityDate |
2007-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |